Chengdu Kanghong Pharmaceutical Group

Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company headquartered in Sichuan, China. Established in 1996, the group operates across pharmaceutical research, development, manufacturing, and distribution. Its portfolio spans ophthalmology, central nervous system medicine, digestive treatments, and endocrine-related therapies. Kanghong's most prominent research program has been conbercept, an anti-vascular endothelial growth factor medicine used in the treatment of retinal diseases, including age-related macular degeneration. The company began developing conbercept in 2005 and later marketed it under the name Lumitin. The product became a central part of Kanghong's ophthalmology activities and provided the group with a platform for further expansion in retinal and other fundus-related diseases. In 2016, the company received authorization from the United States Food and Drug Administration to begin Phase III clinical trials of conbercept, reflecting an effort to extend the product's development beyond its domestic market. By May 2021, Kanghong was reported to have 18 medicines on the market. In addition to Lumitin, named products included Songling Xuemaikang capsules, Keluoxin capsules, Xinluona, Bolexin, Bosiqing, Yitaning, Shugan Jieyu capsules, Danshu capsules, and Yiqing capsules. These products cover a range of therapeutic areas, including ophthalmic disease, digestive disorders, depression and other central nervous system conditions, sleep-related treatment, and traditional or combination medicine categories. The company also maintained a pipeline addressing conditions such as glioma, fundus tumors, diabetic macular edema, and type 2 diabetes. Research and intellectual property have been important to Kanghong's business model. In 2020, research and development expenditure was reported as approximately 29 percent of annual revenue. By that period, the group held 238 patents and exclusive patent rights relating to 13 of its 18 marketed products, according to the cited reference material. These figures indicate a strategy centered on proprietary medicines rather than solely on generic manufacturing or distribution. Kanghong has also expanded its international footprint through subsidiaries and partnerships. The group was reported to have 13 subsidiaries in China, Israel, and the United States. In 2017, it acquired IOPtima, an Israeli subsidiary of BioLight Israeli Life Sciences Investment, and also became a distributor of IOPtima products in China. This transaction broadened Kanghong's ophthalmology capabilities and connected its Chinese commercial network with an Israeli medical-technology and pharmaceutical operation. During the COVID-19 pandemic, Kanghong contributed money, protective clothing, and other supplies to medical institutions in China through the China Red Cross Foundation. The response formed part of the company's public-health and corporate social-responsibility activity during the emergency. Kanghong is therefore best characterized as a China-based pharmaceutical group with a broad domestic product portfolio and a particularly significant ophthalmology franchise. Its strategic profile combines proprietary drug development, clinical-stage innovation, manufacturing, domestic distribution, and selective international expansion. The available reference material does not establish a current corporate website, a named founder, current executives, or a ticker symbol, so those fields remain unspecified here.

Chengdu Kanghong Pharmaceutical Group was established in 1996 in Sichuan, China. It developed as an integrated pharmaceutical enterprise involved in research, development, manufacturing, and distribution. Its therapeutic scope came to include ophthalmology, central nervous system medicine, digestive treatments, and endocrine-related products. A major turning point came in 2005, when Kanghong initiated development of conbercept. The molecule was developed as an anti-vascular endothelial growth factor treatment for retinal disorders, including age-related macular degeneration, and was later commercialized under the name Lumitin. The program became an important part of Kanghong's innovation strategy and its efforts to build a proprietary ophthalmology franchise. In 2016, the United States Food and Drug Administration permitted Kanghong to begin Phase III clinical trials of conbercept. The regulatory step represented an attempt to advance the drug through international development and to establish evidence for markets outside China. Kanghong subsequently broadened its ophthalmology interests through corporate expansion. In 2017, it acquired IOPtima, an Israeli subsidiary of BioLight Israeli Life Sciences Investment, while also becoming a distributor of IOPtima products in China. By 2020, the group reported substantial emphasis on research and intellectual property. Research and development investment was approximately 29 percent of annual revenue, and the company held 238 patents. Exclusive patent rights were reported for 13 of its 18 products. Its development pipeline included potential treatments for glioma, fundus tumors, diabetic macular edema, and type 2 diabetes, indicating an effort to extend beyond its established marketed medicines. By May 2021, Kanghong had 18 medicines on the market. Its portfolio included Lumitin as well as Songling Xuemaikang capsules, Keluoxin capsules, Xinluona, Bolexin, Bosiqing, Yitaning, Shugan Jieyu capsules, Danshu capsules, and Yiqing capsules. These products represented a mix of ophthalmic, neurological, psychiatric, digestive, sleep-related, and other therapeutic applications. The group also developed an international corporate structure, with 13 subsidiaries reported across China, Israel, and the United States. Its international activities combined overseas acquisition, domestic distribution, and the pursuit of foreign clinical development. During the COVID-19 pandemic, Kanghong donated funds, protective clothing, and other supplies to Chinese medical institutions through the China Red Cross Foundation. The available reference material identifies Kanghong as a publicly traded company on the Shenzhen Stock Exchange but does not provide a verified ticker symbol in the supplied information. It also does not identify a founder, current executive team, or an official corporate website. The group's documented development nevertheless shows a progression from a Sichuan-based pharmaceutical manufacturer and distributor into a research-led company with a broad marketed portfolio and a particularly visible focus on ophthalmic innovation.

• 2021

  Reported marketed portfolio of 18 medicines

  [1]Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org

  By May 2021, Kanghong was reported to have 18 drugs on the market and 13 subsidiaries in China, Israel, and the United States.

• 2020

  Research and development expansion

  [1]Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org

  R&D investment was reported at approximately 29 percent of annual revenue, while the company held 238 patents and exclusive patent rights for 13 of its 18 products.

• 2020

  COVID-19 relief contributions

  [1]Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org

  The company donated funds, protective clothing, and other supplies to medical institutions in China through the China Red Cross Foundation.

• 2017

  IOPtima acquisition

  [1]Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org

  Kanghong acquired IOPtima, an Israeli subsidiary of BioLight Israeli Life Sciences Investment, and took on Chinese distribution of IOPtima products.

• 2016

  FDA authorization for Phase III trials

  [1]Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org

  The U.S. Food and Drug Administration authorized Kanghong to begin Phase III clinical trials of conbercept.

• 2005

  Conbercept development begins

  [1]Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org

  Kanghong began development of conbercept, an ophthalmic medicine for retinal diseases including age-related macular degeneration.

• 1996

  Company founded

  [1]Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org

  Chengdu Kanghong Pharmaceutical Group was established in Sichuan, China.

A Chinese research-oriented pharmaceutical group combining proprietary drug development with manufacturing and distribution across ophthalmology, central nervous system, digestive, and endocrine-related therapeutic areas.

• Ophthalmic medicine

  Lumitin

  Lumitin is the commercial name associated with conbercept, Kanghong's major ophthalmology product. Conbercept is an anti-vascular endothelial growth factor medicine used in the treatment of retinal diseases, including age-related macular degeneration. Its development began in 2005 and later progressed to U.S. Phase III clinical-trial authorization.

• Pharmaceutical capsules

  Songling Xuemaikang capsules

  Songling Xuemaikang capsules are among the medicines identified in Kanghong's marketed portfolio. The supplied reference material lists the product but does not provide sufficient detail about its active ingredients, approved indications, or development history.

• Pharmaceutical capsules

  Keluoxin capsules

  Keluoxin capsules are part of Kanghong's marketed product range. The available reference identifies the product by name but does not specify its indication, formulation, or launch date.

• Digestive medicine

  Xinluona

  Xinluona is identified with mosapride citrate and belongs to Kanghong's digestive-system medicine portfolio. The supplied material does not provide further information on its approved uses, dosage forms, or commercial launch.

• Central nervous system medicine

  Bolexin

  Bolexin is identified as venlafaxine hydrochloride capsules, a medicine associated with central nervous system treatment. It was listed among Kanghong's marketed products, although the supplied source does not specify its launch date or detailed commercial positioning.

• Central nervous system medicine

  Bosiqing

  Bosiqing is identified as aripiprazole tablets and forms part of Kanghong's central nervous system portfolio. The supplied reference does not give additional information about the product's indication history or launch timing.

• Sleep-related medicine

  Yitaning

  Yitaning is identified as dexzopiclone tablets and was included among Kanghong's marketed medicines. The available material does not provide further details about its approved indications, market introduction, or sales scope.

• Pharmaceutical capsules

  Shugan Jieyu capsules

  Shugan Jieyu capsules are listed as one of Kanghong's marketed products. The supplied reference does not state their precise indication, composition, launch year, or geographic availability.

• Pharmaceutical capsules

  Danshu capsules

  Danshu capsules are included in the company's reported product portfolio. No further product-specific information is available in the supplied reference material.

• Pharmaceutical capsules

  Yiqing capsules

  Yiqing capsules were identified among Kanghong's marketed medicines. The available source does not provide sufficient detail about their formulation, indication, or launch history.

• 2020COVID-19 medical relief donations

  China

  During the COVID-19 pandemic, Kanghong supplied money, protective clothing, and other materials to medical institutions through the China Red Cross Foundation.

  Outcome. The initiative provided material and financial support to Chinese medical institutions during the public-health emergency.

  Source

• 2017

  Acquisition of IOPtimaM&A

  Background

  Kanghong pursued international expansion in ophthalmology and sought access to overseas products and capabilities.

  Action taken

  The company acquired IOPtima, an Israeli subsidiary of BioLight Israeli Life Sciences Investment, and distributed IOPtima products in China.

  Aftermath

  The transaction expanded Kanghong's international subsidiary network and its Chinese ophthalmology distribution activities.

  Source

• 2016

  International clinical development of conberceptOther

  Background

  Kanghong pursued development of its ophthalmic medicine beyond the Chinese market.

  Action taken

  The company received U.S. FDA authorization to begin Phase III clinical trials of conbercept.

  Aftermath

  The authorization advanced the product's international clinical-development program.

  Source

• 2005

  Commitment to conbercept developmentStrategy

  Background

  Kanghong sought to strengthen its proprietary pharmaceutical pipeline and ophthalmology capabilities.

  Action taken

  The company began developing conbercept for retinal diseases including age-related macular degeneration.

  Aftermath

  The program became a major element of Kanghong's ophthalmic research and product portfolio.

  Source

1. 1Chengdu Kanghong Pharmaceutical Groupen.wikipedia.org